Search research articles
Contact Us
Filters
Showing results (301-310 of 369) with videos related to
Page
of 37
Sort By:
Journal of Neuro-Oncology
|
January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II glioma
J Blaes, M Weiler, F Sahm, et al.
EMBO Molecular Medicine
|
December 16, 2015
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz, Patrick N Harter, Sebastian Cremer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology
|
November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Journal of Neuro-Oncology
|
September 10, 2025
Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT)
Mirjam Renovanz, Melina Hippler, Robert Kuchen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Antje Wick, Oliver Bähr, Martin Schuler, et al.
Cell Death Discovery
|
March 26, 2026
Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma
Iris Divé, Jasmin A Schäfer, Katharina J Weber, et al.
Acta Neuropathologica
|
March 19, 2015
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
Michael Weller, Ruthild G Weber, Edith Willscher, et al.
Trials
|
January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Epilepsy & Behavior : E&B
|
September 18, 2017
Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches
Sebastian Bauer, Natascha van Alphen, Albert Becker, et al.
Page
of 37
Search research articles
Search
Showing results (301-310 of 369) with videos related to
Sort By:
Page
of 37
Journal of Neuro-Oncology
|
January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II glioma
J Blaes, M Weiler, F Sahm, et al.
EMBO Molecular Medicine
|
December 16, 2015
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz, Patrick N Harter, Sebastian Cremer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology
|
November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Journal of Neuro-Oncology
|
September 10, 2025
Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT)
Mirjam Renovanz, Melina Hippler, Robert Kuchen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Antje Wick, Oliver Bähr, Martin Schuler, et al.
Cell Death Discovery
|
March 26, 2026
Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma
Iris Divé, Jasmin A Schäfer, Katharina J Weber, et al.
Acta Neuropathologica
|
March 19, 2015
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
Michael Weller, Ruthild G Weber, Edith Willscher, et al.
Trials
|
January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Epilepsy & Behavior : E&B
|
September 18, 2017
Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches
Sebastian Bauer, Natascha van Alphen, Albert Becker, et al.
Page
of 37